

## Index

Note: Page references in *italics* refer to Figures; those in **bold** refer to Tables

- a**
- α2-macroglobulin 37
  - αIIbβ3 integrin receptor in platelet membrane 134
  - ε-aminocaproic acid 109
  - abnormal uterine bleeding (AUB) 30, 40
    - AUB-C 37
  - abscess, epidural 196
  - acquired von Willebrand syndrome (aVWS) 86
  - activated partial thromboplastin time (APTT) 5, 75, 103, 207
    - in FXI deficiency 122
    - in FVII deficiency 122
    - in VWD 88
  - acupuncture 192
  - ADAMTS13 83, 84
  - adenosine diphosphate (ADP) 142
  - adrenomedullin 39, 40
  - afibrinogenemia 9, 119, 121, 126, 127, 169, 217
  - alkaline hematin test 23, 120
  - alpha granule release assessment 142
  - amniocentesis 128, 144, 170, 172–4, 173, 209
    - third-trimester 173–4
    - in VWD 90
  - angiotensin II receptor type 2 (AGTR2) 40
  - ANKD26 mutations 144
  - antenatal diagnosis *see* prenatal diagnosis (PND)
  - anterior spinal artery syndrome 196
  - antiepileptics 216
  - antifibrinolytics 72, 77, 104
    - in factor XI deficiency 109
    - in heavy menstrual bleeding 55
    - in menorrhagia 127
    - in VWD 91
  - antithrombin 110
  - arachidonic acid 142
  - aromatase 33
  - aspirin 147
  - atherosclerosis 90
- b**
- Bernard–Soulier syndrome (BSS) 21, 50, 145, 147, 214, 215
  - bipolar radiofrequency ablation 57
  - Bleeders Not Yet Defined (NYD) 25
  - Bleeders of Unknown Cause (BUC) 25
  - bleeding assessment tools (BATs) 13–26, 48, 159
    - clinical utility of 25–6
    - condensed MCMDM-1VWD 20
    - evaluation of menstrual blood loss 23–4
    - International Society on Thrombosis and Haemostasis Bleeding Assessment Tool 21
    - molecular and clinical markers for diagnosis and management of Type 1 VWD (MCMDM-1VWD) 14–20
    - Pediatric Bleeding Questionnaire (PBQ) 20–1
    - Self-BAT 21–2
    - Self-PBQ 21–2
    - Vicenza Bleeding Questionnaire and Score 14
    - Vicenza-based, evolution of 13–14, 14, **15–19**
    - women’s studies using Vicenza-based bleeding tools 22–3
    - young women’s hematology and bleeding 25
  - breastfeeding 90
  - broad ligament hematoma 59
  - butorphanol 193

**C**

carbonic anhydrase 9 36  
 Cardiff Penthrane  
   inhaler 192  
 cascade model 4  
 cell-based model of  
   hemostasis 4–5, 4  
 cell-free fetal DNA (cffDNA)  
   in maternal  
   circulation 177  
 central nervous system (CNS)  
   bleeding 136  
 cephalohematoma 209, 211  
 cephalosporins 216  
 cervical cerclage 128  
 cervical lesions 123  
 cervicitis 123  
 cesarean section in factor XI  
   deficiency 108  
 CHAMP FVIII database 153  
 CHBMP database 153  
 chemokines 35  
   C 35  
   CC 35  
   CCL11 35  
   CCL2 35  
   CX3C 35  
   CXC 35  
   CXCL10 35  
   CXCL8 35, 36  
 chorionic villus sampling  
   (CVS) 74, 128, 144,  
   170, 171–2, 209  
   in VWD 90  
 circumcision  
   factor VI deficiency 111  
   in newborn 213  
 Clauss fibrinogen 9  
 clotting factors  
   in heavy menstrual  
   bleeding 56  
   in menorrhagia 127  
 coagulation disorders 215–18  
 coagulation factors,  
   rare 216–18, 217  
 coagulation pathways 3, 37  
 collagen 3, 142  
   collagens I, III, IV and  
   VI 35

combined hormonal  
   contraceptives (COCs)  
   factor XI deficiency and 104  
   in heavy menstrual  
   bleeding 53, 58  
   in menorrhagia 127  
 combined oral contraceptive  
   pill (COCP) 9, 53, 147  
   in VWD menorrhagia 92  
 combined spinal-epidural  
   (CSE) 192, 195  
 Condensed MCMDM-1VWD  
   Bleeding  
   Questionnaire 22, 26  
 congenital amegakaryocytic  
   thrombocytopenia  
   (CAMT) 145, 214  
 congenital bleeding disorders  
   detection 209–13  
   newborns presenting  
   with bleeding  
   symptoms 211–13  
   newborns with positive  
   family history of  
   bleeding  
   disorder 209–11  
   optimal mode of  
   delivery 210–11  
   prenatal  
   diagnosis 209–10  
 developmental  
   hemostasis 205–6  
 diagnostic algorithm 206  
 laboratory hemostatic  
   evaluation 208–9  
 management  
   congenital bleeding  
   disorders 218–21, 220  
   when newborn is  
   bleeding 219–21  
   presentation 213–18  
   primary hemostasis 206–7  
   secondary  
   hemostasis 207–8  
 connective tissue growth  
   factor (CTGF) 40  
 consanguineous  
   marriage 231  
 cordocentesis 170, 174–6, 175

corpus luteum, bleeding  
   from 6  
 cryoablation 57  
 cryoprecipitate 124  
 cumulus oophorus 32

**d**

Danazol 54  
 DDAVP 70, 76, 109, 146  
   in heavy menstrual  
   bleeding 55–6, 58  
   in inherited platelet  
   defects 144  
   nasal spray 58  
   in VWD type 2 and  
   type 3 53  
 deamino-8-arginine  
   vasopressin *see* DDAVP  
 decidualization 34, 35  
 dense granule release  
   assessment 142  
 dental surgery 146–7  
 depot medroxyprogesterone  
   acetate (DMPA) 54  
 desmopressin 55–6, 75, 93,  
   104, 109, 221  
   in factor XI deficiency 110  
   in heavy menstrual  
   bleeding 55–6  
   in hemophilia A 110  
   in menorrhagia 127  
   for menorrhagia in women  
   with VWD 92  
   in VWD 90, 110  
   *see also* DDAVP  
 desogestrel (Cerazette®) 54  
 digital PCR (dPCR) 179  
 disseminated intravascular  
   coagulation  
   (DIC) 109, 214  
 double uterotonics 77  
 droplet digital PCR  
   (ddPCR) 179  
 Duchenne muscular  
   dystrophy 181  
 dural puncture 195  
 dyschezia 59  
 dysfibrinogenemia 9, 121,  
   122, 127

- dysmenorrhea 59  
dyspareunia, deep 59
- e**  
Ehlers--Danlos syndrome 7  
Eltrombopag 147  
embryo culture 181  
endometrial ablation  
  in heavy menstrual  
    bleeding 56–7  
  in menorrhagia 127  
endometrial hyperplasia 60  
endometrial polyps 123  
endometriosis 6, 59–60, 121  
  link between IBM and 60  
endothelin-1 (ET-1) 37  
enflurane 193  
Entonox 192  
enzyme-linked  
  immunosorbent assay  
  (ELISA) 9, 142  
epidural 192  
epidural abscess 196  
epidural hematoma 196, 199  
epinephrine 142  
episiotomy 107  
estradiol 30 1, 33  
estrogen receptor (ER) 33  
  ER $\alpha$  33, 34  
  ER $\beta$  33  
ethinyl estradiol, low-dose 53  
European Association for  
  Haemophilia and  
  Allied Disorders  
  (EAHAD) international  
  database 66, 153  
European Molecular and  
  Clinical Markers for  
  the Diagnosis and  
  Management of Type 1  
  von Willebrand Disease  
  (MCMDM-1VWD)  
  study 20  
European Network of the Rare  
  Bleeding Disorders  
  (EN-RBD) 117  
extracranial hemorrhage (ECH)  
  in newborn 209,  
  211–12
- f**  
factor II *see* prothrombin  
factor V 3  
factor V deficiency 5, 10, 50,  
  117, 122, 126, 169  
  in newborn 217–18  
  postpartum hemorrhage  
    in 121  
  prevalence 117  
factor V + factor VIII deficiency,  
  combined 10, 66, 117,  
  122, 124, 169  
  prevalence 117  
factor Va 5  
factor VII 3, 9, 37, 101  
  postpartum hemorrhage  
    in 122  
factor VII deficiency 5, 10,  
  50, 117, 169  
  in newborn 218  
  prenatal diagnosis 180  
  prevalence 117  
  severe 126, 128  
factor VIIa 101  
factor VIII (FVIII:C) 3, 9, 84  
  in hemophilia, neonate  
    76  
  in pregnancy 192  
factor VIII deficiency 153  
  in newborn 219  
factor VIIIa 5  
factor IX 192  
  in hemophilia, neonate  
    76  
  in pregnancy 192  
factor IX deficiency 5, 153,  
  169, 219  
  *see also* hemophilia B  
factor IXa 4  
factor X 9, 101  
factor X deficiency 10, 50,  
  122, 124, 169  
  in newborn 218  
  prenatal diagnosis 180  
  prevalence 117  
  severe 126, 128  
factor XI 104, 106–7  
  concentrates 109  
  in pregnancy 192  
factor XI deficiency (FXI) 1,  
  10, 45, 59, 101–11, 124,  
  127, 128  
  in Ashkenazi Jews 211  
  bleeding manifestations and  
    diagnosis 103–4  
  coagulation cascade 102  
  gynecological  
    surgery 104–5  
  heavy menstrual  
    bleeding 103–4  
  hysterectomy 104  
  incidence and  
    inheritance 101–3  
  inheritance 169  
  neonatal bleeding 111–12  
  in newborn 218  
  neuroaxial analgesia and  
    anesthesia 108  
  postpartum hemorrhage  
    and 122  
  postpartum period,  
    management of 108–9  
  pregnancy and 105–8,  
    106, 192  
  antenatal  
    management 105  
  bleeding tests 105–7  
  bleeding  
    phenotype 105–6  
  blood group 106  
  factor XI level 106–7  
  fibrin density  
    network 107  
  global testof  
    hemostasis 107  
  labor delivery 107–8  
  in mild/moderate FXI  
    deficiency 108  
  requiring cesarean  
    section 108  
  in severe FXI  
    deficiency 107–8  
  peripartum  
    management 105–7  
  prevalence 117, 118  
  structure and function in  
    coagulation 101, 102  
  treatment 109–11

factor XI replacement therapy 109–10

factor XIa 3, 5

factor XIII 4, 5, 37

factor XIII deficiency 5, 10, 50, 59, 117, 124, 127, 128, 169

miscarriage in 121

in newborn 218, 219

PPH in 121

phenotype 122

prenatal diagnosis 180

prevalence 117

severe 126

fantanyl 193

fibrin 4

fibrinogen 4, 9

in pregnancy 127

fibrinogen deficiency 10, 50, 124, 128

miscarriage in 121

in newborn 217

phenotype 122

prevalence 117

thrombin time (TT) in 122

fibrinolysis 4, 36–7

fibroids 6, 54, 121

factor XI deficiency 104

submucosal 123

uterine 50, 60

fibronectin 3

flow cytometry 142, 143

fluorescent *in situ* hybridization (FISH) 172, 181

follicle aromatase 30

free fetal DNA (ffDNA) 170

free fluid ablation 57

fresh frozen plasma (FFP) 104, 109, 110, 124

FSH 30

**g**

gene therapy in Wiskott–Aldrich syndrome 147

genetic counselling 167–70

clinical phenotype 169

confirmation of diagnosis 168

inheritance 168

reproductive options 169, 70

genome editing 147

Glanzmann thrombasthenia 21, 50, 137, 144–5, 146, 147, 214, 215

in French gypsies 211

glycoprotein Ib 3

glycoprotein Ib-IX-V complex 134

glycoprotein IIb/IIIa platelet receptor 3

glycoprotein VI 3, 134

gonadotrophin-releasing hormone 30

agonist in heavy menstrual bleeding 54

pulse generator 31

gonadotrophins 30

gray platelet syndrome 214

growth factor binding protein-1 35

gynecology 45–61

**h**

heat shock proteins 1A and 1B 40

heavy menstrual bleeding (HMB) 1, 37, 40, 45, 47, 47, 48–9, 119–21, **20**

algorithm of management 51

diagnosis 45–6

endometriosis 59–60

IBD and **49–50**

management 51–2

incidence 29

investigations 50–1

management of acute episodes 58

COCs 58

LNG-IUS 58

nasal DDAVP spray 58

medical treatment 51–8

hormonal treatments 51–5

non-hormonal treatments 55–6

surgical interventions 56–8

ovulation bleeding 59

as predictor for bleeding disorders 46–7

screening for bleeding disorders in 47–8

hemarthroses 136, 213

hematoma

broad ligament 59

epidural 196, 199

muscle 136

in newborn 213

retroperitoneal 59

spinal 196, 199

subgaleal 209, 211

hematopoietic stem cell transplantation in inherited platelet defects 145

hemoperitoneum 59

hemophilia 5

prenatal diagnosis of 177–80, 178

hemophilia A (HA) 5, 22, 57, 117, 192, 215

desmopressin in 110

FVIII:C levels 154, 155

genetic analysis 160–2

guidelines 164

inheritance 168

phenotypic analysis 154–6

prevalence 153, **154**

severity 154

variant types **160**

variants 153

hemophilia A, carriers of 65–79, 192

bleeding disorders in 68–73

FVIII or FIX deficiency 68–9

FVIII:C/FIX:C levels and bleeding scores in 71

imprecise designation with low factor level 70

- low FVIII or FIX
  - levels 69
  - menorrhagia 72
  - prevalence 70
  - protection from thrombosis 73
  - terminology 69–70
  - treatment of bleeding episodes 70–1
  - type of bleeding episodes 72
- care of carriers 77–9
- delayed genetic diagnosis/ carriership 68
- F8 or F9 gene mutation 66
- genetic vs coagulation testing 66–7
- inheritance 65, 66
- pregnancy in 73–7
- preimplantation genetic diagnosis (PGD) 67
- prenatal diagnosis (PND) 67
- quality of life 73
- screening of 65–6
- timing of genetic testing 67–8
- vignettes 78–9
- hemophilia B 5, 117, 215, 222
  - in Amish communities 211
  - FIX:C levels 156
  - genetic analysis 162–3
  - guidelines 164
  - inheritance 65, 66, 168
  - phenotypic analysis 156–7
  - in pregnancy 192
  - prevalence 153, **154**
  - severity 154
  - variant types **160**
  - variants 153
- hemophilia B, carriers
  - of 65–79
  - bleeding disorders
    - in 68–73
    - FVIII or FIX deficiency 68–9
    - FVIII:C/FIX:C levels and bleeding scores in 71
  - imprecise designation
    - with low factor level 70
  - low FVIII or FIX levels 69
  - menorrhagia 72
  - prevalence 70
  - protection from thrombosis 73
  - terminology 69–70
  - treatment of bleeding episodes 70–1
  - type of bleeding episodes 72
- care of carriers 77–9
- delayed genetic diagnosis/ carriership 68
- F8 or F9 gene mutation 66
- genetic vs coagulation testing 66–7
- inheritance 65, 66, 168
- pregnancy in 73–7
- preimplantation genetic diagnosis (PGD) 67
- prenatal diagnosis (PND) 67
- quality of life of carriers 73
- screening of 65–6
- timing of genetic testing 67–8
- vignettes 78–9
- hemorrhage
  - extracranial (ECH) 209
  - intracranial (ICH) 68, 76–7, 209, 212, 212
  - see also* postpartum hemorrhage
- hemostasis
  - cell-based model of 4–5, 4
  - defects of 5
  - fibrinolysis 4
  - normal 1–3, 2
  - primary 3
  - secondary 3–4
- hemostatic function platelet function analyzer (PFA-200) 89
- hemostatic risk 191–2
- heparin 109
- hepatitis A and B viruses 91
- Hermansky–Pudlak syndrome 145
- high forceps 210
- hormone replacement therapy (HRT) 9, 60
- hyperplasia 6, 121
- hypofibrinogenemia 9, 121, 127, 217
  - PPH in 122
- hyponatremia 90
- hypoprothrombinemia 169
- hypothalamic-pituitaryovarian axis 31, 32
- hypoxia inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ) 36, 39
- hysterectomy
  - in heavy menstrual bleeding 57–8
  - in menorrhagia 127
- hysteroscopy 50, 57
- i**
- immune thrombocytopenias (ITPs) 214
- immunoglobulin 109
- in vitro* fertilization (IVF) 181, 210
- inherited bleeding
  - disorder (IBDs) 1–10, 45, 48
  - bleeding, clinical
    - presentation of 5–6
  - diagnosis 6
  - heavy menstrual bleeding and **49–50, 61**
  - history 6–7, 7
    - medication history 6
    - pastmedical history and family history 6
- investigations 7–10
  - hemostatic assays
  - laboratory assessment of hematological and coagulation system 7, **8–9**
  - preanalytical factors in coagulation testing 9–10

- investigations (*Contd.*)  
 specialized tests of  
   coagulation 10  
 physical assessment 6–7  
 prevalence 13  
 phenotypic analysis  
   of 157–60  
 inherited platelet defects  
   (IPDs) 10, 133–48,  
   213–15  
   case histories 147–8  
   causative gene **138–41**, 143  
   future directions 147  
   investigation 137–43  
   management 144–7  
     dental surgery 146–7  
     menorrhagia 147  
     pregnancy and  
       delivery 145–6  
     supportive  
       management 147  
     surgery 146–7  
     treatment options 144–5  
 normal platelet  
   function 133–4  
 prenatal diagnosis 143–4  
 presentation 136–7  
 inherited thrombocytopenias  
   134, 136  
   related to GATA-1  
     mutations 314  
 integrin receptor  $\alpha 2\beta 1$  134  
 interleukin (IL)  
   IL-6 35  
   IL-15 35  
 intermenstrual bleeding,  
   irregular 60  
 International Society on  
   Thrombosis and  
   Haemostasis (ISTH)  
   Scientific and Standardization  
   Committee  
   (SSC) 13–14  
 International Society on  
   Thrombosis and  
   Haemostasis Bleeding  
   Assessment Tool  
   (ISTH-BAT) 6, 21,  
   22, 25, 137  
 international normalized ratio  
   (INR) 207  
 intracranial hemorrhage (ICH)  
   68, 76–7  
   in newborn 209, 211–12,  
   212  
 intracytoplasmic sperm  
   injection (ICSI) 181  
 intramuscular analgesia  
   193  
 intravenous opioid  
   administration 193  
 iron deficiency 48  
 iron deficiency anemia 50  
 isoflurane 193  
 isoniazid 216
- k**  
 kisspeptin 31
- l**  
 labor pain 191  
   non-pharmacological  
     management 192  
   pharmacological  
     management 192–  
     201  
   general anesthesia 201  
 inhalation  
   analgesia 192–3  
   opioid analgesia 193–4  
   postoperative pain 201  
   regional (neuraxial)  
     analgesia and  
     anesthesia 194–9  
 coagulopathy and risk of  
   neurological  
     complications 195–6  
 guidance for use in  
   IBDs 198–9, **198**, **200**  
 regional blockade in  
   IBD 197–8  
 risks and complications 195  
 techniques of blockade  
   194–5  
   regional block techniques,  
   other 199–201  
 paracervical block 199–200  
 pudendal block 200–1  
 laminin 3  
 Lebanon  
   inherited bleeding disorders  
     in 225  
   inherited factor VII  
     deficiency 230–1, 232  
   type 3 VWD 229–30, 231  
 leptin 31  
 levonorgestrel 53  
 levonorgestrel intrauterine  
   device (IUD) 159  
   in menorrhagia 127  
 levonorgestrel intrauterine  
   system (IUS)  
   factor XI deficiency  
     and 104  
   in menorrhagia 147  
 levonorgestrel-releasing  
   intrauterine device 92  
 levonorgestrel-releasing  
   intrauterine system  
   (LNG-IUS) in heavy  
   menstrual  
   bleeding 51–2, 52, 58  
 light transmission aggregometry  
   (LTA) 142, 143  
 loss of resistance  
   technique 194  
 low molecular weight heparin  
   in VWD 94  
 lumiaggregometry 21, 142  
 luminometry 142  
 lupus anticoagulant 9  
 lyonization 68
- m**  
 macrophages 36  
 macrothrombo  
   cytopenias 214  
 Malaysia 232  
   inherited bleeding disorders  
     in 225–9  
   Glanzmann  
     thrombasthenia 228,  
     231  
   VWD type 2 227–8,  
   231, 232  
 massively parallel sequencing  
   (MPS) 179

- matrix metalloproteinases (MMPs) 36, 37
- MCMDM-1VWD Bleeding Questionnaire 20, 26
- mean platelet volume (MPV) 134
- Mediterranean microthrombotic cytopenia 214
- medroxyprogesterone acetate 58
- megakaryocytes 133
- menarche 31
- menorrhagia 5–6, 26, 70, 119–21, **120**  
 differential diagnosis 123–4  
 IPDs presenting with 136  
 management 147  
 vWD and 87–8, 91, 92
- menstrual blood loss (MBL) 45–6
- menstrual cup (Mooncup®) 46
- menstruation 29–40  
 control of bleeding 37–8  
 endometrial regeneration 40  
 endometrial repair 38–9  
 endometrium 33–4  
 neuroendocrine hormones 30–1  
 normal menstruation 29–30  
 duration 30  
 volume of blood loss 30  
 ovarian follicle development and endocrine function 31–3  
 physiology of 29–31  
 proliferative phase 40  
 secretory phase 34–5
- meperidine 193, 194
- meptazinol 193
- mesenchymal-to-epithelial transition (MET) 39
- methoxyflurane 192
- miscarriages 121
- Mittelschmerz (midcycle pain) 59
- molecular and clinical markers for the diagnosis and management of Type 1 VWD (MCMDM-1VWD) 14–20  
 condensed 20
- monogenic diseases (MGD) 181
- morphine 193
- mucocutaneous type bleeding 209
- muscle hematomas 136
- musculoskeletal bleeding 209
- MYH9-related disorder 137, 142, 214
- MYH9-related thrombocytopenia 147
- n**
- naloxone 193
- natural killer (NK) cells 34
- neonatal alloimmune thrombocytopenia 137, 146
- next-generation sequencing (NGS) 10, 143
- NF-κB 36
- nitrous oxide 193
- non-invasive prenatal diagnosis (NIPD) 176–7
- non-resectoscopic endometrial ablation (NREA) 56
- non-steroidal anti-inflammatory drugs (NSAIDs) 55, 72, 93, 147
- norethisterone 58
- NovoSeven® in inherited platelet defects 144–5
- o**
- obstetric cholestasis 196
- ocular albinism 7
- oral progesterone tablets 147
- ovarian cyst hemorrhagic 6, 59, 61, 121  
 ruptured 61, 137
- ovulation bleeding 59
- oxytocin 195
- p**
- pain, definition 191
- Pakistan, inherited bleeding disorders in, type 3 VWD 225–7, 231, 232
- PALMCOEIN acronym 30
- patient-controlled analgesia (PCA) 193
- patient-controlled epidural analgesia (PCEA) 194
- Pediatric Bleeding Questionnaire (PBQ) 20–1, 25, 26  
 Self 21–2
- pelvic pain, chronic 59
- petechiae 209
- pethidine 193
- PGE2 37
- PGF2α 36, 37
- Phillipp screening tool 24, 25
- Pictorial Blood Assessment Chart (PBAC) 23–5, 23–4, 46, 104, 120, 136, 159, 232
- plasmin 4, 37
- plasminogen 37, 207
- plasminogen activator inhibitor (PAI) 37
- platelet activation 3
- platelet activation status 134
- platelet adhesion 3
- platelet aggregation 3, 134
- platelet beta 1 integrin 3
- platelet count 134
- platelet formation 134, 135
- platelet function analyzer (PFA)-100
- platelet function disorders 5, 45, 103, 214–15
- platelet granules 134  
 alpha 134  
 dense 134
- platelet plug formation 3

- platelet transfusion in inherited platelet defects 145
- Poiseuille's equation 37, 38
- polyps 6, 121  
endometrial 123  
factor XI deficiency 104  
uterine 50, 60
- postcircumcision  
bleeding 209
- postmenopausal bleeding (PMB) 60
- postpartum hemorrhage (PPH) 6, 70, 77, 87–8, 103, **120**, 121–2  
in factor XI deficiency 105
- pre-eclampsia 90, 196
- pregnancy in hemophilia  
carriers 73–7  
antenatal management 73–5  
changes of factor levels 74–5  
preimplantation genetic diagnosis (PGD) 74  
prenatal diagnosis 73–4  
perinatal management 75–7  
cranial imaging 76  
intracranial hemorrhage and relation to mode of delivery 76–7  
mother - regional block 75  
neonate 75–6  
postpartum hemorrhage 77
- preimplantation embryo selection (PIES) 210
- preimplantation genetic diagnosis 181–3  
carrier attitudes 183–4  
experiences and psychological effects 184–5  
towards prenatal diagnosis 183–4  
termination of pregnancy 184, 185
- Premarin 58
- prenatal diagnosis (PND) 167–85  
carrier attitudes towards 183–4  
of factor VII, factor X and factor XIII deficiencies 180  
of hemophilia 177–80, 178  
invasive 170–6  
non-invasive (NIPD) 176–7  
of rare bleeding disorders 180–1  
of VWD 180
- primary hemostasis 83
- prion diseases 91
- progesterone 30, 34, 35–6
- progesterone receptor (PR) 33  
PRA 34  
PRB 34
- progestin-only “mini-pill” 54
- progestogens in heavy menstrual bleeding 53–4, 58
- prostaglandin E2 35
- prostaglandin F2 $\alpha$  35
- protease tissue plasminogen activator (tPA) 4
- prothrombin 5, 9, 37
- prothrombin complex concentrates (PCCs), 124, 126
- prothrombin deficiency 10, 50, 126  
in newborn 217  
PPH in 122  
prevalence 117
- prothrombin time (PT) 5, 207
- puberty *see* menarche
- purpura 209
- r**
- rare bleeding disorders (RBDs) 117–28  
classification **126**  
clinical symptoms 118–19  
differential diagnosis in menorrhagia 123–4  
gender 118  
global distribution 118  
gynecological and obstetrical manifestations 119–22  
laboratory diagnosis 122–3  
phenotype 122  
molecular diagnosis 122–3
- prenatal diagnosis of 180–1  
treatment 124–8, **125**  
clotting factor replacement 124–7  
management of pregnancy and childbirth 127–8  
treatment of menorrhagia 127
- receiver operator curve (ROC) 20–1
- recombinant factor VIIa (rFVIIa) 109, 110–11, 126  
in inherited platelet defects 144–5
- recombinant factor XIIIa 104, 126
- recombinant VWF concentrate 91
- relative haplotype dosage (RHDO) 179–80
- relative mutation dosage (RMD) 179
- remifentanyl 193, 194, 202
- resectoscope 56
- resectoscopic endometrial ablation (REA) 56–7
- restriction fragment length polymorphisms (RFLPs) 177
- retrograde menstruation theory 59
- retroperitoneal hematoma 59
- rifampin 216
- ristocetin 142, 215
- ristocetin co-factor assay, VWF:RCo 89
- rotational thromboelastometry (ROTEM) 10
- RUNX1 mutation 144



**s**

Self-BAT 21–2  
 Self-PBQ 21–2  
 sevoflurane 193  
 solvent detergent (SD) FFP 110  
 spinal hematoma 196, 199  
 subgaleal hematoma 209, 211  
 submucosal fibroids 123  
 Swyer syndrome 68

**t**

termination of  
   pregnancy 184, 185  
   hemophilia A and B  
     and 73–4  
 thermal balloon ablation 57  
 thrombin 3, 4, 5, 37  
 thrombin activatable  
   fibrinolysis inhibitor  
   (TAFI) 5, 101  
 thrombin generation test  
   (TGT) 107  
 thrombocytopenia 37, 146,  
   213–14  
   inheriteds 134, 136, 314  
 thrombocytopenia with absent  
   radii (TAR) 214  
 thromboelastography  
   (TEG) 10, 107  
 thromboelastometry  
   (ROTEM) 107  
 tissue factor (TF) 3, 37, 101  
 tissue factor pathway inhibitor  
   (TFPI) 101  
 tissue inhibitors of  
   metalloproteinases  
   (TIMPSs) 38  
 tissue plasminogen activator  
   (u-PA) 37  
 tramadol 193  
 tranexamic acid 6, 93, 94,  
   108, 109, 127, 147, 197  
   factor XI deficiency 104  
   in heavy menstrual  
     bleeding 55  
   in inherited platelet  
     defects 144  
   for menorrhagia in  
     VWD 92

  in VWD 91  
 transcervical endometrial  
   resection 57  
 transdermal contraceptive  
   patches 53  
 transforming growth factor  $\beta$ 2  
   (TGF $\beta$ 2) 40  
 Tuohy's curved bevel  
   needle 194, 195, 196  
 Turner syndrome 68, 156

**u**

Ulipristal acetate (UPA)  
   (Esmya<sup>®</sup>) in heavy  
   menstrual  
   bleeding 54–5  
 ultra-large (ULVWF) VWF  
   multimers 207  
 ultrasound examination,  
   fetal 170  
 umbilical stump  
   bleeding 212  
 ureteric silk catheters 194  
 urokinase-like plasminogen  
   activator (uPA) 4  
 uterine fibroid 50, 60  
 uterine natural killer (uNK)  
   cells 34–5  
 uterine polyps 50, 60  
 uterine tony 121

**v**

vaccines 212–13  
 vacuum extraction 210  
 vaginal rings 53  
 vaginal tears 107, 123  
 valerate and dienogest (E2V/  
   DNG) contraceptive  
   pill 53  
 variant Creutz-Jakob  
   disease 91  
 vascular endothelial growth  
   factor (VEGF) 36  
   VEGFR-1 (flt-1) 39  
   VEGFR-2 (KDR) 39  
   VEGR 39, 40  
 venepuncture 212–13  
 vessel radius, effect on on  
   blood flow 37, 38

## Vicenza Bleeding

  Questionnaire and  
   Score 14  
 vitamin K 76, 146  
   at birth 211, 212–13  
   metabolism 122  
 vitamin K deficiency bleeding  
   (VKDB) in  
   infancy 216  
 vitamin K-dependent  
   coagulation factor  
   deficiency (VKCFD)  
   117, 122  
 von Willebrand disease  
   (VWD) 1, 5, 6, 9, 37,  
   45, 47, 57, 83–96, 103,  
   117, 142, 215–16  
   cases 94–6  
   classification and  
     inheritance 85, **86**  
   clinical presentation 87  
   diagnosis 10, 13, 14, 88–9  
     inheritance 168–9  
     VWF:Ag levels 154  
   family testing 89–90  
   genetic analysis 163–4  
   genetic analysis 89–90  
   guidelines 164  
   gynecological bleeding,  
     management of 91  
   history 83  
   inheritance 168–9  
   laboratory testing 88–9  
   management 90–1  
   menorrhagia and 87–8,  
     91, 92  
   neonatal management 94  
 obstetric  
   management 92–4  
   antenatal  
     management 92–3  
   intrapartum  
     management 93  
   postpartum  
     management 93–4  
   pre-pregnancy  
     management 92  
 phenotypic analysis 157,  
   **158**

- von Willebrand disease (VWD) (*Contd.*)
    - postpartum hemorrhage and 87–8
    - prenatal diagnosis 89–90, 180
    - platelet-type VWD 214
    - type 1 85, 87–8, 89, 90, 92, 93, 153
      - normal clotting factor levels 192
    - type 2 48, 53, 85, 89, 90, 92, 93, 153
    - type 2A 169
    - type 2B 169, 214
    - type 2M 154, 169
    - type 2N 154, 169
    - type 3 48, 53, 85–7, 89–90, 92, 93–4, 153, 219
      - inheritance 169
      - in pregnancy 192
      - variance 153
  - von Willebrand factor (VWF)
    - 3, 5, 9, 37, 47, 103
    - deficiency 153
    - levels and prevalence of VWD 84
    - menorrhagia and 87–8
    - menstrual cycle, pregnancy and 84–5
    - postpartum hemorrhage and 87–8
    - structure and function 83–4
  - von Willebrand factor antigen (VWF:Ag. VWF:Ac) 192
  - von Willebrand syndrome, acquired (aVWS) 86
  - von Willebrand factor pseudogene (VWFP1) 153
  - VWF *see* von Willebrand factor (VWF)
- W**
- warfarin 216
  - Willebrand disease (VWD) 66
  - Wiskott–Aldrich syndrome (WAS) 145, 147, 214
  - World Federation of Hemophilia (WFH) 117
- X**
- X-linked thrombocytopenia 147